The CDC made a strong recommendation based on a high certainty of evidence to use the long-acting injectable lenacapavir ...

Lenacapavir is a long-acting injectable antiretroviral drug developed by Gilead Sciences. It is administered just twice a year and has demonstrated over 99.9% effectiveness in preventing HIV ...

Gilead surges 26.5% YTD in 2025 as HIV franchise gains momentum with Yeztugo approval, offsetting cell therapy pressures.

The scope of FDA warnings about compounded drugs is narrower than messaging suggests, because they do not center on the ...

HIV, the virus that causes AIDS, could be eliminated in Canada as early as 2030, if enough people at risk get tested and, if ...

From influenza and COVID-19 to HIV, viruses continue to pose a serious danger to global health. But just as pressing are ...

Lenacapavir, approved by the FDA in June, requires only two shots a year. US insurers don't cover it, but access will soon ...

More than 50% of HIV diagnoses now occur in 48 counties in the United States. Cuyahoga County, home to Cleveland, is one of ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

WASHINGTON (AP) — The U.S. is purchasing enough doses of a new twice-a-year HIV prevention shot to share with up to 2 million people in poor countries by 2028, the State Department announced Thursday.